Testing rifaximin to prevent diarrhea from pelvic radiotherapy in cancer patients
Tests rifaximin to prevent diarrhea caused by pelvic radiation in adults with cancer.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 1/2
Where in Egypt
- Mansoura UniversityAl Mansurah, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT06783153
- Record updated
- 20 January 2025
- Original description
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.Read full original descriptionShow less
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Inclusion: Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers; Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
Exclusion: Patients who have a record of intestinal resection in their medical history; Patients who regularly take anti-diarrheal medications before commencing radiotherapy; Patients with a medical background of irritable bowel syndrome; Patients with a history of inflammatory bowel disease; Patients with compromised immune systems, such as those who are HIV positive or using immunosuppressive medications; Patients allergic to rifamycin; Patients experiencing diarrhea at the outset of the study; Pregnant or lactating woman.